EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tissue-targeted regulators of complement for amelioration of human disease: rationale and novel therapeutic strategies

Fei Liu, Stefan Wawersik, Stephen Tomlinson, Joshua M Thurman, V Michael Holers

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkaf053 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Fei Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Q32 Bio Inc., Waltham, MA, United States. Hauptthemen laut MEDLINE: Complement Activation, Complement System Proteins, Autoimmune Diseases, Complement Inactivating Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The complement system is an essential part of innate immunity, and dysregulated complement is an underlying driver in many inflammatory and autoimmune diseases. Currently approved complement-focused therapeutics rely on systemic blockade of complement activation, but a major challenge with this approach is that complement components exist in high abundance and undergo rapid systemic turnover, creating a large pharmacologic sink. To improve the arsenal of complement therapies, tissue-targeting has emerged as a strategy to re-regulate complement in diseased tissue, while limiting systemic blockade. This approach, which is based on directing complement modulators to tissues through the recognition of tissue-fixed activated complement fragments, tissue-specific epitopes, or injury-associated neoepitopes, has the potential for enhanced potency and durability and reduced infection risk. In this review, we discuss the rationale for tissue-targeted complement therapies, the strategies taken to achieve local regulation, current state of preclinical and clinical stage tissue-targeted therapeutics, and potential future directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Complement ActivationComplement System ProteinsAutoimmune DiseasesComplement Inactivating AgentsHumansAnimalsImmunity, Innate

Stichwörter der Autor:innen

complementcomplement regulatorstissue-targeted therapeutics

Substanzen

Complement System ProteinsComplement Inactivating Agents

Autor:innen und Institutionen

  • Q32 Bio Inc., Waltham, MA, United States.
  • Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, United States.
  • Ralph Johnson VA Medical Center, Charleston, SC, United States.
  • Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, United States.
  • Division of Rheumatology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, United States.

Zitieren

APA

Liu, F., Wawersik, S., Tomlinson, S., Thurman, J. M., & Holers, V. M. (2025). Tissue-targeted regulators of complement for amelioration of human disease: rationale and novel therapeutic strategies. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf053

Vancouver

Liu F, Wawersik S, Tomlinson S, Thurman JM, Holers VM. Tissue-targeted regulators of complement for amelioration of human disease: rationale and novel therapeutic strategies. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf053

BibTeX
@article{Liu2025,
  author = {Liu, Fei and Wawersik, Stefan and Tomlinson, Stephen and Thurman, Joshua M and Holers, V Michael},
  title = {Tissue-targeted regulators of complement for amelioration of human disease: rationale and novel therapeutic strategies},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkaf053}
}
Kostenlos starten →